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Objectives: Programmed death-ligand 1 (PD-L1) expression is a biomarker for cancer immunotherapy. Diabetes
mellitus type-2 is a comorbid disease associated with adverse outcomes in Non-Small Cell Lung Cancer (NSCLC).
We aimed to investigate the differences in PD-L1 expression in diabetics.
Methods: A matched case-control cohort of surgically-resected NSCLC was assembled from an early multicenter
study (PMID: 19152440). PD-L1 immunohistochemistry (Clone 22C3) was graded by a tumor positive score
(TPS) system (TPS0: no staining; TPS1: <1%; TPS2: 1–49%; TPS3: ≥50%). Variables showing significance at
univariate survival analysis were fit in a Cox regression survival model.
Results: Diabetics (n=40) and nondiabetics (n=39) showed no differences in age, gender, cancer stage, and
follow-up. NSCLCs were more likely PD-L1 positive in diabetics but with tumor positivity <50% (TPS0: 7.5 vs.
20.5%, TPS1: 35 vs. 25.6%, TPS2: 45 vs.23.1%, TPS3: 12.5 vs. 30.8%, respectively; P<0.05). In diabetics,
squamous cell carcinomas (SCC) and adenocarcinomas were mainly TPS2 (65% vs. 20%) and TPS1 (50% vs.
26%), respectively. Peritumoral inflammation correlated with TPS (r=0.228), a relationship accentuated in
diabetics (r=0.377, P<0.05) but diminished and non-significant in nondiabetics (r=0.136, P≥0.05). This as-
sociation was stronger in SCC (r=0.424). Diabetes was associated with increased tumor recurrence (HR: 3.08;
95%CI: 1.027-9.23).
Conclusion: Diabetes is associated with an increase in peritumoral inflammation, PD-L1 positivity, and recur-
rence in NSCLC, more pronounced in SCC, suggesting the possibility of metabolic reprogramming and upre-
gulation of PD-L1 by inducible pathways.
Introduction
Lung cancer remains the leading cause of cancer death in women
and men worldwide [1]. Non-small cell lung cancer (NSCLC) accounts
for 80% of all lung cancer cases with a low 5-year survival rate. For
early-stage NSCLC, surgery and adjuvant therapies are available as
primary treatment [2]. Hyperglycemia is among the factors associated
with a worsened prognosis in NSCLC [3–6]. The prevalence of diabetes
mellitus (DM) type 2 in patients with lung cancer varies between 5%
and 28% and has been associated with a higher risk of all-cause mor-
tality [4,5]. A large metanalysis revealed that diabetes is a risk factor
for death from lung cancer after adjustment for age, sex, smoking
status, and body mass index (BMI) [7]. An adverse effect of diabetes on
local recurrence in patients with surgically resected NSCLC was de-
monstrated in a multicenter study and confirmed in a subsequent
smaller cohort [8,9]. Overall, this data supports the role of diabetes in
https://doi.org/10.1016/j.ctarc.2020.100170
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facilitating tumor progression in NSCLC.
Hyperglycemia by itself could explain the adverse effect of DM
because it can contribute to a more aggressive cancer phenotype in-
cluding apoptosis inhibition and chemotherapy resistance [10]. In a
similar cohort selected for the present study, tumor recurrence corre-
lated with an increased expression of Epithelial-to-Mesenchymal
Transition (EMT) phenotype markers in diabetic compared to non-
diabetic patients [11]. Lung adenocarcinomas with an EMT phenotype
overexpress Programmed Death-Ligand 1 (PD-L1) and are associated
with higher amounts Programmed Cell Death-1 (PD-1)+ tumor in-
filtrating lymphocytes [12]. Of interest, there is evidence that poor
glycemic control in patients with diabetes causes immune dysfunction,
a relationship that remains to be proven in NSCLC [13]. It is well-
known that intrinsic tumor factors such as tumor immunogenicity and
tissue microenvironments can modulate tumor PD-L1 expression [14];
however, the effect of comorbid systemic diseases such as diabetes on
tumor PD-L1 expression is mostly unknown. In this study, we aim to
investigate whether DM type 2 influences the tumor expression of PDL-
1 and tumor recurrence in patients with NSCLC when compared to
nondiabetics.
Methods
Study Design
Newly diagnosed, surgically-resected NSCLC cases were selected
from a well-characterized cohort of an early multicenter study [8,9,11].
That study evaluated retrospectively the impact of surgical, histo-
pathologic, and some patient-related factors on the risks of local and
distant recurrence for patients with mostly early stage NSCLC and no
neoadjuvant or adjuvant radiotherapy who were treated between 2000
and 2005. DM was identified as a risk factor for local recurrence in
multivariate analysis [8]. For our study, the sample size was calculated
given an anticipated incidence for diabetics of 65%, for control (non-
diabetics) of 20%, enrollment ratio of 1:1, alpha error of 0.01, and
power of 95%. The anticipated incidence were the local recurrence
ratios estimated in prior Varlotto et al. studies [8,9,11]. This resulted in
a case group (diabetics) of N1=39 and a control group of N2=39 to
assess the association of diabetes with PD-L1 expression. The cases
meeting the inclusion criteria were patients with DM type 2 and pri-
mary adenocarcinoma (ADC) or squamous cell carcinoma (SCC) of the
lung without previous malignancies or neoadjuvant or adjuvant che-
moradiotherapy. Patients with DM type 1 and cases lacking paraffin-
embedded tissue or adequate documentation for the diagnosis of dia-
betes were excluded. Variables included for the analysis were history of
DM type 2, glycosylated hemoglobin (Hb1AC) at the time of excision,
BMI (kg/m2), peripheral blood neutrophil to lymphocyte ratio (NLR),
pathologic tumor (pT) stage, local (ipsilateral thorax and pN1-N3
nodes) and distant lymph node metastasis at the time of excision. A
similar cohort was evaluated in a recent study correlating the expres-
sion of EMT markers with diabetes [11]. Parameters of tumor staging
were updated to the AJCC cancer staging system, 8th edition. Ad-
ditionally, the number of months to recurrence, months to death,
number of recurrences (local and distant), and death events associated
with cancer progression were compiled.
Histopathologic Evaluation
Tumor hematoxylin and eosin (H&E) glass slides were reviewed to
evaluate the NSCLC histologic type, the presence of tumor necrosis and
features of tumor inflammation. Tumor necrosis was documented either
focal or extensive. Assessment of tumor inflammation included grading
of peritumoral inflammation using a 4-tier system: absent (none), mild/
focal (<10% of tumor area), moderate (10-50%), and diffuse (>50%),
and a 2-tier system: cold tumor (absent, mild/focal) and hot tumor
(moderate, diffuse) (Fig. 1). Additionally, predominant inflammatory
cell (neutrophilic, lymphocytic, lymphoplasmacytic, or mixed in-
flammation), increased intraepithelial lymphocytes (defined as the
presence of more than occasional cells within the neoplastic epithelial
component excluding the tumor stroma and in areas away from necrotic
debris), increased intraepithelial neutrophils, and intraepithelial NLR
were evaluated qualitatively.
PD-L1 Immunohistochemistry
PD-L1 immunohistochemical (IHC) assays were performed in for-
malin-fixed paraffin-embedded tissue with the maximum amount of
viable tumor using the Monoclonal Mouse Anti-PD-L1 (DAKO, Clone
Fig. 1. Examples of peritumoral (A-D)
and intraepithelial inflammation (E-F).
A. SCC with focal peritumoral lym-
phocytic aggregates (arrow, 100x). B.
ADC with mild peritumoral inflamma-
tion (arrow, 200x). C. SCC with mod-
erate peritumoral inflammation (100x).
D. ADC with severe peritumoral in-
flammation (100x). E. SCC with few
intraepithelial lymphocytes (arrows)
and no neutrophils typical of a case
with low neutrophil-to-lymphocyte
ratio (400x). F. SCC with numerous
intraepithelial neutrophils (arrows) ty-
pical of a case with high neutrophil-to-
lymphocyte ratio (400x). All pictures
correspond to hematoxylin and eosin
staining.
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22C3), DAB+ Substrate-Chromogen revealing system and autostainer
Dako ASL48 according to the manufacturer's protocol [15]. Appropriate
positive and negative controls were run simultaneously. PD-L1 IHC
testing was previously validated at our laboratory.
PD-L1 Expression Scores
A board-certified pathologist (N.R.) assessed all stained slides for
PD-L1 expression independently, in a blinded fashion. Tumor
Proportion Score (TPS), percentage of viable tumor cells showing par-
tial or complete membrane staining at any intensity, was evaluated
based on the 4-tier system of the International Association for the Study
of Lung Cancer (IASLC) guideline as follows: TPS0: no staining; TPS1:
<1%; TPS2: 1-49%; and TPS3: ≥50% [16] (Fig. 2).
Statistical Analyses
Although the features of the cohort included in this research were
explored previously [8], a new independent analysis was performed in
order to assure homogeneity between diabetic and nondiabetic patients
and to adjust the analysis of recurrence to the new variables in-
corporated herein. Patient's characteristics were compared using pooled
and Satterthwaite t-tests for parametric data, and Fischer's Exact and
Chi-square tests for nonparametric data in SAS (V.9.0; Cary, NC, USA)
system software. For univariate analysis, the survival was estimated
using Kaplan-Meier curves and compared with the Log-Rank and Bre-
slow (Generalized Wilcoxon) tests. For multivariate analysis, all vari-
ables showing statistical significance at the univariate analysis were fit
with a Cox regression (proportional hazard) model. Hazard ratios (HR)
with 95% confidence interval (CI) were calculated, and the results
under the best fit model are shown. Spearman correlation test was used
for categorical variables. The survival and correlation analyses were
performed in SPSS (version 22.0; Chicago, Illinois, USA) system soft-
ware. The graphs were designed in Prism 5 software (version 6;
GraphPad Software Inc, La Jolla, CA, USA). Statistical significance was
considered with two-sided P-values less than 0.05.
Results
Patient's characteristics
A total of 79 patients with NSCLC (ADC: 39, SCC: 40) were selected
to assemble a cohort of patients with diabetes (n=40; 50.63%) and
nondiabetics (n=39; 49.37%) for final analysis. No significant differ-
ence in the distribution of age, gender, peripheral blood NLR, pT stage,
metastasis, cancer histologic type, and tumor necrosis between dia-
betics and nondiabetics was observed (Table 1). A total of 20 patients
with DM type 2 had HbA1C levels within a range of 7.5–7.7% at the
time of excision. HbA1C levels were not measured in 14 diabetics and
all nondiabetics at the time of excision. Obesity (BMI greater or equal
than 30 Kg/m2) was observed more frequently in diabetics (18;
46.15%) as compared to nondiabetics (9; 23.08%) (P<0.001).
Features of the NSCLC-associated inflammation
The entire cohort was relatively homogeneous regarding the fea-
tures of tumor inflammation (Table 1). NSCLCs in patients with dia-
betes showed more often moderate peritumoral inflammation (52.5%
vs. 33.3%) while mild/focal peritumoral inflammation was more
common in tumors of nondiabetics (12% vs. 41%) (P<0.01). When the
Fig. 2. Examples of PD-L1 expression scores: TPS0 (negative, A), TPS1 (<1%, B), TPS2 (1-49%, C), TPS3 (≥50%, D). All pictures correspond to PD-L1 im-
munostaining (DAKO, Clone 22C3) at medium magnification (200x).
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variable peritumoral inflammation was dichotomized by grouping
mild/focal with none in one category (“cold” tumor) and moderate with
diffuse in a second category (“hot” tumor), no significant statistical
difference between diabetics (cold: 30%; hot: 70%) and nondiabetics
(cold: 43.6%; hot: 56.4) was observed (P=0.256). NSCLCs in both
groups showed similar percentage distributions according to the vari-
ables of predominant inflammatory cell, increased intraepithelial lym-
phocytes, increased intraepithelial neutrophils, and peripheral blood
and intraepithelial NLRs (Table 1).
For the entire cohort, diabetic patients, SCC and ADC cases, peri-
tumoral inflammation (4-tier and 2-tier systems) did not correlate with
peripheral blood and intraepithelial NLRs (Fig. 3). However, the pro-
portion of cases with a peripheral blood NLR ≥5 increased in higher
grades of peritumoral inflammation in nondiabetics only (r=0.368,
P<0.05). There was a weak correlation between peripheral blood and
intraepithelial NLRs (r=0.129, P=0.344). Cases with increased in-
traepithelial (≥1) NLRs were more common in SCC than in ADC (22%
vs. 2.6%, P<0.05, Fisher's Exact test). Increased peripheral blood (≥5)
NLRs was also more frequent in SCC cases, but it was not statistically
significant (51.7% vs. 29.6%, P≥0.05, Fisher's Exact test). Although the
distribution of peritumoral inflammation grades was similar between
SCC and ADC (P=0.783, Fisher's Exact test), SCCs presented more
frequently than ADCs with increased intraepithelial lymphocytes (50%
20/40 vs. 23.07% 9/39, respectively, P<0.05), and increased in-
traepithelial neutrophils (42.5% 17/40 vs. 2.5% 1/39, respectively,
P<0.0001).
DM type 2 is associated with increased NSCLC recurrence rate
The follow-up time in both cohorts was compared to detect any
variation in drop-out rates. There was no significant difference in
follow-up time between diabetics and nondiabetics (48.76± 46.71 vs.
44.72±34.86 months respectively, mean± SD, P=0.664) (Fig. 4).
Furthermore, the distribution of cases on the follow-up timeline was
homogenous. Roughly, 50% were followed-up for 3 years or more, 25%
for 5 years or more, and 25% for 7 months or less in both cohorts. The
average survival in patients with diabetes was 148.3 months versus
104.3 months in nondiabetics, a difference that was not statistically
significant (P=0.597, Log-Rank test; P=0.666, Breslow test). Events of
tumor recurrence were more frequent in diabetics (12 events) than
nondiabetics (6 events). However, this difference was not significant in
univariate analysis (P=0.128, Log-Rank test; P=0.101 Breslow test). A
multivariate Cox regression analysis adjusted by metastasis and obesity
(significant for increased tumor recurrence in univariate analysis),
showed that diabetes was associated with increased tumor recurrence
(HR: 3.08; 95% CI: 1.027-9.23), (Fig. 4). None of the other variables
including tumor necrosis, cancer type, intraepithelial lymphocytes, in-
traepithelial neutrophils, and peripheral blood and intraepithelial NLRs
showed a significant impact on tumor recurrence.
NSCLC PD-L1 positivity and percentage of PD-L1 expression in diabetic
versus nondiabetic patients
In the entire cohort, the expression of PD-L1 exhibited a moderate
correlation with peritumoral inflammation (r=0.306, P<0.01) and
increased intraepithelial lymphocytes (r=0.313, P<0.05). While ne-
gative expression was predominantly observed in tumors with focal/
mild inflammation (45.5%), low and moderate expression (TPS1 and
TPS2) were associated with moderate inflammation (45.8% and 48.1%,
respectively) and high expression (TPS3) with diffuse inflammation
(41.2%). Furthermore, high proportions of cold tumors were observed
in TPS0 (54.5%), and hot tumors in TPS1, TPS2, and TPS3 (54.2%,
70.4%, and 76.5%, respectively). The relationships between PD-L1
Table 1
Patient's characteristics and tumor inflammation features of diabetics and
nondiabetics with NSCLC selected for this study.
Variable Diabetics Nondiabetics P-value
N 40 39 -
Age (years)
Mean 67 69.07 0.26*,†
SD 7.50 8.83
Range 55-82 46-88
Gender
Frequency
(Subgroup %)
F:15 (53.85%)
M:25 (46.15%)
F: 21 (37.50%)
M:18 (62.50%)
0.14‡
0.17§
HbA1C at diagnosis (%)
< 6.5 5 (12.82%) 0 <0.001‡§
≥ 6.5 20 (51.28%) 0
NA 14 (35.9%) 39 (100%)
BMI (kg/m2)
<30 13 (33.33%) 30 (76.92%) <0.001‡§
≥30 18 (46.15%) 9 (23.08%)
NA 8 (20.51%) 0
Peripheral blood NLR
<5 13(32.5%) 10(25.6%) 0.77‡§
≥5 12 (30%) 11(28.2%)
NA 15 (37.5%) 18 (46.2%)
pT stage
1a 10 (25%) 15 (38.5%) 0.59‡§
1b 6 (15%) 4 (10.3%)
2a 17 (42.5%) 12 (30.8%)
2b 3 (7.5%) 5 (12.8%)
3 4 (10%) 3 (7.7%)
Lymph node metastasis
None 31 (77.5%) 31 (79.49%) 0.93‡
Local 4 (10%) 3 (7.69%) 1.00§
Distant 5 (12.5%) 5 (12.82%)
Cancer histologic type
Frequency
(Subgroup %)
ADC: 20 (50%)
SCC: 20 (50%)
ADC: 19
(48.72%)
SCC: 20
(51.28%)
0.90‡
1.00§
Tumor necrosis
No 18 (46.15%) 20 (52.63%) 0.56‡
Yes 21 (53.85%) 18 (47.37%) 0.65§
Peritumoral inflammation
Frequency (Subgroup %)
None 7 (17.5%) 1 (2.6%) <0.01§
Mild/ Focal 5 (12.5%) 16 (41%)
Moderate 21 (52.5%) 13 (33.3%)
Diffuse 7 (17.5%) 9 (23.1%)
Predominant inflammatory
cell Frequency (Subgroup %)
None 7 (17.5%) 1 (2.6%) 0.16§
Lymphocyte 10 (25%) 13 (33.3%)
Neutrophil 0 0
Lymphoplasmacytic 19 (47.5%) 19 (48.7%)
Mixed 4 (10%) 6 (15.4%)
Increased intraepithelial
lymphocytes
No 27 (67.5%) 23 (59%) 0.48‡§
Yes 13 (32.5%) 16 (41%)
Increased intraepithelial
neutrophils
No 32 (80%) 29 (74.4%) 0.55‡
Yes 8 (20%) 10 (25.6%) 0.60§
Intraepithelial NLR
<1 37 (92.5%) 32 (82.1%) 0.16‡
≥1 3 (7.5%) 7 (17.9%) 0.19§
⁎ Pooled t- test.
† Satterthwaite t-test.
‡ Chi-Square.
§ Fisher's Exact Test. F: female. M: male. BMI: Body mass index. ADC: ade-
nocarcinoma. SCC: squamous cell carcinoma. NA: not available. NLR: neu-
trophil to lymphocyte ratio. Local metastasis defined as spread to ipsilateral
thoracic lymph nodes.
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expression and NLRs were nonsignificant statistically (Table 2). None-
theless, the category TPS2 (1–49%) was the only one to show an in-
creased number of cases with high peripheral blood NLR (60% vs.
11.1% in TPS0, 36.8% in TPS1, and 37.5% in TPS3).
NSCLC in nondiabetics showed a relatively equal distribution across
TPS categories as follows: TPS0 (negative): 20.5% (8/39), TPS1
(<1%):25.6% (10/39), TPS2(1-49%): 23.1% (9/39), and TPS3
(>50%): 30.8% (12/39). Diabetics comprised NSCLC tumors likely to
be positive for PD-L1 immunostains, but those tumors largely showed
TPS of less than 50%: TPS0 (negative): 7.5% (3/40), TPS1 (<1%):35%
(14/40), TPS2 (1–49%): 45% (18/40), and TPS3 (>50%): 12.5% (5/
40) (Fig. 5). The difference between TPS categories in diabetics and
nondiabetics was statistically significant (P<0.05 Chi-square test;
P<0.05 Fisher's Exact test). Despite there was no significant difference
Fig. 3. Percentage frequency distribution of cases according to grade of peritumoral inflammation (none, mild/focal, moderate, and severe) and peripheral blood (A)
and intraepithelial (B) neutrophil to lymphocyte ratios in the entire cohort, diabetic and nondiabetic patients, and squamous cell carcinoma (SCC) and adeno-
carcinoma (ADC) cases.
Fig. 4. Overall distribution of follow-up time (A) and Kaplan–Meier estimated curves for the two cohorts, diabetics (dotted line) and nondiabetics (non-dotted line),
as a fraction of NSCLC recurrence-free survival (B) with corresponding adjusted hazard ratios (HR) (C, asterisk: P<0.05). Follow-up time is shown with lines marking
the median and interquartile range in A (P-value, t-test).
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in PD-L1 expression between ADC and SCC cases (P=0.8 Chi-square
test; P=0.78 Fisher's Exact test), the distribution of TPS categories
according to diabetes diagnosis differed between cancer histologic
types. For instance, SCC in diabetic patients showed higher amounts of
cases in the TPS2 category in comparison to nondiabetics (65%, 13/20
vs. 20%, 4/20). On the other hand, ADC in diabetic patients showed a
predominant distribution in the TPS1 category (50%, 10/20 vs. 26%, 5/
19).
The positive relationship of PD-L1 expression with peritumoral in-
flammation was more pronounced in patients with diabetes (r=0.377,
P<0.05) but diminished and non-significant in nondiabetics (r=0.136,
P≥0.05). Similar correlation analyses applied to the variable's obesity,
tumor necrosis, peripheral blood and intraepithelial NLRs, increased
intraepithelial lymphocytes and neutrophils, and metastasis failed to
reveal a significant link. The association of diabetes with increased
proportions of hot tumors in higher TPS categories was also heightened
in SCC (r=0.424 vs. r=0.181 (nondiabetics)) and ADC cases (r=0.337
vs. r=0.079 (nondiabetics)). Finally, in univariate and multivariate
survival, PD-L1 expression was not a prognostic factor for tumor re-
currence (adjusted HR vs. TPS3: 1.260, 95% CI: 0.155-10.21) in the
entire cohort. The size of the cohort and amount of PD-L1 negative
cases were too small to perform a dichotomized survival analysis of PD-
L1 expression (negative versus positive) in diabetics and nondiabetics.
Discussion
The primary goal of our investigation was to obtain comparable
cohorts for evaluating the effect of DM type 2 on PD-L1 tumor ex-
pression in NSCLC. Accordingly, the groups of patients with diabetes
(n=40) and nondiabetics (n=39) selected for this study were homo-
genous with matched age, gender, cancer stage, histologic type, tumor
inflammation, NLRs and presence of tumor necrosis. Overall, diabetes
appears to have a positive effect on PD-L1 expression in NSCLC. The
expression of PD-L1 is under controlled of several biological processes
[17]. Briefly, there is a constitutive expression under the control of
genetic mechanisms and an inducible expression triggered by the pre-
sence of some T-cell subsets. Constitutive PD-L1 surface tumor expres-
sion is usually diffuse (>50%), while in those with inducible expres-
sion, the location of PD-L1+ cancer cells correlates with peritumoral
lymphocytic aggregates and tends to be focal (<50%) [17]. Diabetes
was associated with increased tumor PD-L1 positivity but at less than
50%, and the fact that the amount of heavily inflamed NSCLC increased
proportionately in higher TPS categories, suggest that inducible ex-
pression of PD-L1 was upregulated. It is unclear why this relationship
did not extend to the TPS3 category (>50%). Specifically, 30.8% of
non-diabetics had a PD-L1 tumor proportion score higher than 50% vs.
only 12.5% of patient with diabetes. Perhaps, the growth of tumors
with constitutive PD-L1 expression is not favored in diabetic patients,
and the positive effect is restricted to some NSCLC phenotypes. We
postulate that by reducing blood glucose levels, the inflammatory
milieu of tumors can be reduced and the production of PD-L1 could
decrease.
Diabetes may promote a neoplastic process by several mechanisms
including hyperinsulinemia stimulating tumor growth following the
activation of insulin-like growth factor (IGF) receptors, and hypergly-
cemia feeding cancer cells with aerobic glycolysis (the Warburg effect).
Elevated levels of inflammatory molecules that enhance cancer cell
survival, invasion or suppressing anti-tumor immunity also plays a role
[18]. Indeed, PD-L1 expression correlates with high glucose metabolism
in clinical and experimental models. In an in vitro cell line model of
NSCLC, higher PD-L1 expression was accompanied by increased glucose
uptake, suggesting the existence of a potential pathway of im-
munosuppression induced by increased tumor glucose catabolism [19].
Moreover, NSCLCs with higher glucose uptake measured by 8F-fluor-
odeoxyglucose PET/CT display higher rates of PD-L1 positivity [20]. In
a mouse sarcoma model, the blockage of PD-L1 with antibodiesTa
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impaired the tumor ability to burn glucose by decreasing the expression
of glycolytic enzymes. PD-L1 was a direct regulator of tumor glucose
utilization, and both PD-L1 expression and glycolytic activity were
necessary to mediate T-cell hyporesponsiveness [21]. These results
support the concept that cellular phenotypes characterized by increased
glycolytic metabolism and concomitant high PD-L1 expression are part
of coordinated immunosuppressive and pro-survival responses during
cancer progression, which are likely to be potentiated in patients with
diabetes.
Previously, we showed that the same cohort of NSCLCs included in
the presented study demonstrated significantly higher expression of
IGF-1 receptor, transforming growth factor-beta (TGF-β), vimentin, and
N-cadherin, while the expression of HtrA1 and E-cadherin were de-
creased in diabetic patients [11]. This immunoprofile is characteristic
of NSCLC cells with EMT phenotype. Cancer cells undergoing EMT may
be the same as those with PD-L1 overexpression and high glycolytic
activity, possibly comprising a set of clones with a more aggressive
biologic behavior that is favored in patients with diabetes. Tumor EMT
is enhanced by Warburg effect-type metabolism and can be prevented
by disrupting either glucose uptake or glycolytic pathways [22,23].
Furthermore, PD-L1 overexpression in a mouse model of cervical cancer
cells correlated with an increase in glucose uptake mediated by the
promotion of EMT pathways [24]. PD-L1 has also been shown to
mediate the induction of EMT in the human esophageal cancer cell line
Eca-109 [25]. A recent study revealed that PD-L1 positivity was sig-
nificantly higher in lung adenocarcinomas with “mesenchymal” or EMT
phenotype [12]. This evidence supports that PD-L1 is involved in the
acquisition of EMT characteristics along with abnormal glucose meta-
bolism.
The association of diabetes with tumor PD-L1 expression was
Fig. 5. Percentage frequency distribution of PD-L1 expression (DAKO, Clone 22C3) according to the diagnosis of diabetes mellitus type 2 and peritumoral in-
flammation in the entire cohort (A-C), squamous cell carcinoma (SCC) cases (D-F), and adenocarcinoma (ADC) cases (G-I).
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stronger in SCC than ADC (Fig. 5). As compared to ADCs, SCCs have
been associated with a higher glycemic index, preferential elevation of
the GLUT-1 transporter (increased glucose uptake and glycolytic de-
pendency), diabetes, and diets high in saturated fats [26–28]. SCCs in
diabetic patients exhibited a skewed distribution of PD-L1 expression to
the TPS2 (1–49%) category (65% of all SCCs) while ADCs were to the
TPS1 (<1%) category (50% of all ADCs). In the entire cohort, SCCs
showed a significant increase in intraepithelial lymphocytes and neu-
trophils, and peripheral blood and intraepithelial NLRs. Interestingly,
TPS2 tumors displayed higher grades of peritumoral inflammation and
relatively higher proportions of increased NLRs (Table 2). A retro-
spective review of surgical specimens suggests that SCCs can evolve
with CD8+ tumor-infiltrating lymphocytes within cancer nests, and
such infiltrates are associated with a survival benefit at early stages
[29,30]. It is possible that hyperglycemia in diabetic patients in-
tensified the expression of PD-L1 in SCCs with conspicuous tumor-as-
sociated inflammation and increased NLR, promoting rapid tumor
progression by inducing immune dysfunction.
Our findings have potential therapeutic implications. Blockage of
the PD-1 receptor or its ligand PD-L1 with monoclonal antibodies is a
major strategy for promoting T-lymphocyte-mediated anti-tumoral
immune responses, improving the survival as monotherapy or in com-
bination [31,32]. Although there is no universal prognostic biomarker
to predict clinical response to anti-PD-1/PD-L1 therapies, PD-L1 posi-
tivity on IHC assays correlates with an excellent clinical benefit[33].
Increased tumor PD-L1 expression in patients with diabetes type 2
suggests that this NSCLC subgroup may greatly benefit from immune
checkpoint inhibitors. Upon review of the literature, no clinical studies
have addressed whether the efficacy of PD-L1 inhibitors changes in
diabetic patients with either NSCLC or any other form of cancer.
Nevertheless, a recent study proved, across multiple species and tumor
models, that obesity causes PD-1-mediated T cell dysfunction and re-
markably left tumors markedly more responsive to checkpoint blockage
[34]. It is conceivable that diabetes type 2, like obesity, can promote
tumor growth and recurrence by immune dysregulation, but para-
doxically, this could make checkpoint inhibitors more effective.
Conclusion
In summary, diabetes mellitus type 2 is an extra-tumoral (extrinsic)
independent variable that was associated with higher tumor PD-L1
positivity and increased tumor recurrence in NSCLC. Our results in-
dicate that patients with diabetes type 2 may be candidates for PD-L1
inhibitors, especially in those with SCC. The positive effect of diabetes
on PD-L1 expression is more pronounced in NCSLC with significant
peritumoral inflammation. Taking into consideration prior observations
of increased EMT in the same cohort of diabetic patients with NSCLC, it
is possible that diabetes can boost the survival and growth of tumor
cells skilled in metabolizing glucose through the Warburg pathway as
part of a tumor metabolic reprogramming, inducing cancer cell EMT
and creating an immunosuppressive microenvironment by upregulation
of PD-L1 by inducible pathways. The precise molecular mechanism
involved in altered PD-L1 tumor expression in patients with diabetes
remains to be determined.
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